PWE-045 Vedolizumab results in reduced hospitalisation and steroid use over 1-year:results from the scottish vedolizumab cohort

Plevris, Nikolas; Chuah, Cher Shiong; Jenkinson, P; Allen, R; Baker, Paul R. S.; Brennan, Paul; Din, Shahida; Donoghue, Emma; Gaya, Daniel R.; Groome, M; Jafferbhoy, Hasnain; Jones, Gareth; Macdonald, Jonathan; MacMaster, Morag; Mowat, Craig; Naismith, Graham; Noble, CL; Potts, Laura; Saffouri, E; Seenan, JP; Sengupta, Anirban; Shand, Alan G.; Shasi, P; Todd, J; Veryan, Jennifer; Watson, Anne; Watson, Eleanor; Watts, David; Arnott, Ian; Lees, Charlie W.

doi:10.1136/gutjnl-2018-bsgabstracts.177

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vedolizumab responders also appear to have persistence of benefit, with long-term follow-up data from the GEMINI-2 study showing that, of responders at week 6 for whom data were available, 83% were in remission after 2 years and 89% after 3 years 500. Observational studies have shown consistent findings—for example, a Scottish retrospective study of 153 patients had 1 year steroid-free remission of 28.6% 501. The Swedish SWIBREG study reported 147 patients with active Crohn’s disease (86% of whom had previously failed anti-TNF therapy) showed 1 year clinical remission of 54% 502.…”

Section: Crohn’s Diseasementioning

confidence: 89%

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

Lamb

Kennedy

Raine

et al. 2019

Gut

1,501

1,816

View full text Add to dashboard Cite

Ulcerative colitis and Crohn’s disease are the principal forms of inflammatory bowel disease. Both represent chronic inflammation of the gastrointestinal tract, which displays heterogeneity in inflammatory and symptomatic burden between patients and within individuals over time. Optimal management relies on understanding and tailoring evidence-based interventions by clinicians in partnership with patients. This guideline for management of inflammatory bowel disease in adults over 16 years of age was developed by Stakeholders representing UK physicians (British Society of Gastroenterology), surgeons (Association of Coloproctology of Great Britain and Ireland), specialist nurses (Royal College of Nursing), paediatricians (British Society of Paediatric Gastroenterology, Hepatology and Nutrition), dietitians (British Dietetic Association), radiologists (British Society of Gastrointestinal and Abdominal Radiology), general practitioners (Primary Care Society for Gastroenterology) and patients (Crohn’s and Colitis UK). A systematic review of 88 247 publications and a Delphi consensus process involving 81 multidisciplinary clinicians and patients was undertaken to develop 168 evidence- and expert opinion-based recommendations for pharmacological, non-pharmacological and surgical interventions, as well as optimal service delivery in the management of both ulcerative colitis and Crohn’s disease. Comprehensive up-to-date guidance is provided regarding indications for, initiation and monitoring of immunosuppressive therapies, nutrition interventions, pre-, peri- and postoperative management, as well as structure and function of the multidisciplinary team and integration between primary and secondary care. Twenty research priorities to inform future clinical management are presented, alongside objective measurement of priority importance, determined by 2379 electronic survey responses from individuals living with ulcerative colitis and Crohn’s disease, including patients, their families and friends.

show abstract

Section: Crohn’s Diseasementioning

confidence: 89%